Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 (Xeomin) in Upper Facial Lines
NCT04594213Phase 3Completed
- Sponsor
- Merz
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of incobotulinumtoxinA in glabellar rhytides, forehead rhytides and lateral canthal rhytides (3 arms), sponsored by Merz. Primary endpoints: Percentage of Glabellar Frown Line Responders at Day 30, Percentage of Horizontal Forehead Lines Responders at Day 30 and 1 more. Started Sep 2020; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
glabellar rhytidesforehead rhytideslateral canthal rhytides
Beyond the preview
Go deeper on NCT04594213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594213.